PFE
Pfizer Inc
27.70$
+0.1%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -14.0% | +9.6% | +3.6% | -3.9% | -20.5% | +14.4% | +126.2% | -10.2% | -70.3% | +46.5% | -8.2% | |
| – | -6.9% | +11.6% | +8.9% | +1.8% | -5.9% | -20.5% | +8.7% | -2.4% | +24.2% | +11.5% | -6.0% | |
| – | +14.2% | +3.3% | +21.6% | +13.0% | -24.3% | +5.3% | +56.3% | -26.2% | -39.8% | +67.0% | -8.9% | |
| – | +138.2% | -38.9% | -262.8% | – | – | +0.8% | -353.2% | – | – | – | – | |
| – | -60.4% | -84.9% | +1,424.7% | -171.5% | – | – | – | -134.8% | – | – | – | |
| – | -5.5% | +33.6% | +10.9% | -0.9% | +18.1% | +7.6% | -2.9% | +19.4% | +20.7% | -25.5% | -9.6% | |
| – | -47.3% | +162.1% | -39.3% | – | -187.2% | +8.3% | +427.9% | -30.0% | +104.5% | – | -150.9% | |
| – | +5.0% | +5.4% | +4.7% | +4.2% | +0.8% | +4.9% | +3.4% | +2.9% | +2.9% | +2.9% | +2.7% | |
| – | +23.2% | -18.8% | +0.0% | +144.0% | -27.3% | – | -100.0% | – | -100.0% | – | – | |
| – | +137.9% | +97.0% | -139.1% | -7.0% | – | -245.5% | -91.4% | +218.8% | – | -119.9% | -99.0% | |
| – | +2.5% | -12.8% | +46.1% | +56.8% | -58.5% | +13.7% | +1.7% | +51.1% | – | -165.8% | -39.9% | |
| – | -74.3% | -451.0% | – | – | – | +280.0% | -66.7% | -1,058.9% | – | -173.9% | – | |
| – | -14.9% | +6.8% | +2.5% | -4.4% | -26.7% | +16.2% | +157.2% | -12.8% | -81.6% | +105.2% | -7.7% |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.